Illinois-based, specialty pharmaceutical and medication delivery company Hospira (HSP) agreed to acquire Australia-based Mayne Pharma Limited (MYP), a specialty injectable pharmaceuticals company, for $2 billion.
Under the terms of the agreement, Mayne shareholders will receive AUD$4.10 cash per outstanding ordinary share of Mayne, or a total equity consideration of approximately AUD$2.6 billion (US$2.0 billion), including options.
The deal represents a 32 percent premium over Mayne's Sept. 18, 2006 closing price.
Hospira Chief Executive Officer Christopher Begley said:
Further financial details of the agreement are described in Hospira's and Mayne's press releases."This combination will create the leading generic injectable pharmaceuticals company in the world – delivering unparalleled value to the global healthcare system as well as our respective shareholders and employees."
Comment Preview